Nomura Asset Management Co. Ltd. Raises Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Nomura Asset Management Co. Ltd. grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 91,374 shares of the biopharmaceutical company’s stock after acquiring an additional 4,531 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $29,796,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Bayforest Capital Ltd increased its position in Alnylam Pharmaceuticals by 14.6% in the first quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 39 shares during the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Alnylam Pharmaceuticals by 32.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock worth $58,000 after buying an additional 44 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 13,170 shares of the biopharmaceutical company’s stock worth $4,295,000 after buying an additional 45 shares during the last quarter. Fulton Bank N.A. raised its position in shares of Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Fulton Bank N.A. now owns 1,421 shares of the biopharmaceutical company’s stock valued at $463,000 after buying an additional 46 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Alnylam Pharmaceuticals by 10.3% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company’s stock valued at $142,000 after acquiring an additional 49 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on ALNY. Canaccord Genuity Group boosted their price objective on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. UBS Group increased their price target on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a report on Friday, August 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 8th. BMO Capital Markets boosted their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Finally, Stifel Nicolaus increased their target price on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the company a “buy” rating in a research note on Monday, October 6th. Twenty-three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $482.17.

Insider Buying and Selling

In related news, Director Colleen F. Reitan sold 18,000 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the completion of the sale, the director owned 775 shares in the company, valued at $362,390. This trade represents a 95.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the business’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the completion of the sale, the executive vice president directly owned 54,052 shares of the company’s stock, valued at approximately $24,434,206.60. This trade represents a 6.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 56,200 shares of company stock worth $25,709,053 over the last ninety days. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $462.30 on Wednesday. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The business’s fifty day simple moving average is $458.52 and its two-hundred day simple moving average is $387.70. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The firm has a market cap of $61.08 billion, a price-to-earnings ratio of -187.17 and a beta of 0.30.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.